Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    ATA Publishes Revised Guidelines for Managing Thyroid Cancer - (DGNews)
    Brain Tumours In Childhood Leave a Lasting Mark On Cognition, Life Status - (DGNews)
    Patients With Diverticulosis May Require Less Aggressive Screening for Colonic Polyps: Presented at ACG - (DGDispatch)
    High Definition Colonoscopy Increases Polyp Detection: Presented at ACG - (DGDispatch)
    Ascorbic Acid-Based Prep Improves Bowel Cleansing, Increases Small Adenoma Detection Rate During Colonoscopy: Presented at ACG - (DGDispatch)

    News archive

     Recent webcasts/CME - Oncology Other
    • Questioning Clinical Assumptions in Accelerated-Phase and Blast-Crisis CML
    • Carcinoid Tumors of the Gastrointestinal Tract
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Multidisciplinary Approach to Management of Neuroendocrine Tumors
      Cancer and Venous Thromboembolism: Current Clinical Issues

      Webcasts/CME archive

       Recent cases - Oncology Other
        Giant Thoracic Schwannoma Presenting with Abrupt Onset of Abdominal Pain: A Case Report
        Novel Deployment of a Covered Duodenal Stent in Open Surgery to Facilitate Closure of a Malignant Duodenal Perforation
        Clinical Experience of Novel Interconnected Porous Hydroxyapatite Ceramics for the Revision of Tumor Prosthesis: A Case Report
        Superior Vena Cava (SVC) Reconstruction Using Autologous Tissue in Two Cases of Differentiated Thyroid Carcinoma Presenting with SVC Syndrome
        Surgical Treatment of a Giant Tibial High-Grade Mixofibrosarcoma with Preservation of Limb Function: A Case Report

        Cases archive
          




        my personal edition > oncology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Palifermin Helps Reduce Incidence of Oral Mucositis in Patients Undergoing HSCT; More Studies Needed: Presented at MASCC/ISOO

        By Louise Gagnon

        TORONTO, CANADA -- June 27, 2006 -- Palifermin reduces the incidence of oral mucositis than does standard therapy in patients undergoing haematopoietic stem cell transplantation (HSCT), but larger studies are needed to warrant its use on a wider scale, according to an Australian study presented here at the meeting of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO).

        Mucositis is a complication that occurs commonly in patients who undergo HSCT, said Pam Horsley, a dietician with the Wesley Hospital in Brisbane, Queensland, Australia, and principal investigator of the study.

        The study compared treatment with palifermin, a recombinant form of human keratinocyte growth factor, in 32 patients and 27 historical controls to determine if the drug would improve severe mucositis, swallowing problems, and nutritional intake, amongst other indicators. Patients who have undergone HSCT are typically on analgesic opioids, such as morphine, to provide pain relief, noted Ms Horsley.

        "There was a significant decline in oral mucositis [48% vs 3%, standard care vs palifermin, respectively, P = .003]," said Ms Horsley. "We also found there to be a significant difference in length of stay, [18 vs 14 days, respectively, P = .026] as well as the number of nutrition impact symptoms [4.9 vs. 6.0, respectively, P = .003]."

        There were, however, no significant differences in the rate of infection, nutritional status, dietary intake, use of total parenteral nutrition, analgesic dose and duration of administration of opioid analgesics, and time to engraftment, between patients who received palifermin and controls.

        Despite the difference in nutrition impact symptoms between patients on palifermin and controls, there was no gain in dietary intake or nutritional status, noted Horsley.

        "Looking at it from a nutritionist's point of view, there was no significant different in oral intake," said Ms Horsley. "We expected to see a decrease in infection with palifermin because previous research has shown this, but we did not see any reduction."

        The study has not resulted in the adoption of palifermin at Wesley Hospital on a widespread basis, but has been limited to patients judged to be at high-risk for severe mucositis.

        "We still need to do larger trials to confirm our results in terms of efficacy and side effects," concluded Ms Horsley.

        Amgen, makers of palifermin, supplied the drug for the study, but did not provide additional financing.


        [Presentation title: Palifermin Improves Severe Mucositis, Swallowing Problems, Nutrition Impact Symptoms and Length of Stay in Patients Undergoing Hematopoietic Stem Cell Transplant, abstract 16-096]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send